Research Applications
Selective anticancer therapy. HDM-2-positive tumors. Pancreatic cancer research. Combination with conventional chemotherapy.
Mechanism of Action
PNC-27 binds to HDM-2 overexpressed on cancer cell surfaces. The MRR domain anchors in the membrane, while the p53 domain binds HDM-2, causing peptide oligomerization and membrane pore formation. This induces rapid necrotic cell death specific to HDM-2-expressing cancer cells.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All Protocols





